ISSN: 2167-0870
Department of Medical Science, Boston University School of Medicine, Boston, United States
Research Article
Patient- Reported Reasons for a COVID-19 Therapeutics Clinical Trial: Findings from a Multi-Center Investigation
Author(s): Samira Reyes Dassum*, Ryan Ferguson, Patricia Woods, Maura Flynn, Karen Visnaw, Erika Holmberg, Sara Schiller, Colleen Shannon, Mary Brophy, Paul Monach, Sarah Leatherman and Westyn Branch-Elliman
Background: Early in the COVID-19 pandemic, no evidence proven therapeutics were available, and thus
participation in a clinical trial was often the only way to access experimental therapeutic options. In the US,
participation in medical research is low, and patient stated factors driving non-enrollment decisions are poorly
characterized. Thus, the aim of this study was to identify patient and legally-authorized representative reported
reasons for declining enrollment in a COVID-19 therapeutics trial identify potential strategies for addressing barriers
in future investigations.
Methods: As part of a pragmatic randomized trial during the period from 4/10/20-2/3/21, SARS-CoV-2 positive
inpatients with moderate to severe disease were screened for eligibility. If eligible patients declined to participate, they
were asked an ope.. View More»
DOI:
10.35248/2167-0870.22.12.508